NextPlat Corp (NASDAQ: NXPL) boosts Q2 2026 margins, sharply narrows net loss

Q: How did NextPlat Corp (NXPL) perform financially in Q2 2026?

NextPlat reported $11.9 million in Q2 2026 revenue and a net loss of $144,000 . Revenue grew 21% sequentially, gross margin reached 40%, and management notes underlying profitability excluding a one-time $0.5 million professional-fee increase.

Q: How did NextPlat’s Q2 2026 results compare to the prior year for NXPL?

Q2 2026 revenue was $11.9 million versus $13.2 million in Q2 2025, while net loss narrowed to $144,000 from $1.8 million. Gross margin improved significantly to 40% , up from 22% in the prior-year quarter.

Q: What drove margin improvement for NextPlat Corp (NXPL) in Q2 2026?

NextPlat’s overall gross margin reached 40% , helped by Healthcare Operations margin of 46% and e-Commerce margin of 27% . Growth in higher-margin 340B contracted pharmacy services and satellite-based IoT and PTT products supported this expansion.

Q: What is the status of NextPlat’s balance sheet as of June 30, 2026?

As of June 30, 2026, NextPlat had $11.9 million in cash, total assets of $28.7 million , and total liabilities of $12.2 million . Working capital was about $14.2 million , and the company reported no material unsecured debt.

Q: What strategic initiatives did NextPlat Corp (NXPL) highlight for its healthcare business?

NextPlat emphasized higher-margin 340B contracted pharmacy services , signing 11 new entities in the first half of 2026. It also disclosed an intended acquisition of a profitable pharmacy in Northwest Florida and plans to launch a nationwide medication fulfillment website in Q3 2026.

Q: How did NextPlat’s e-commerce segment perform in Q2 2026?

E-commerce revenue increased 27% sequentially to about $4.1 million with gross margin rising to 27% . Growth was driven by satellite-based connectivity, IoT, and Push-to-Talk hardware plus airtime services, with government and military sales surpassing $1.75 million year-to-date.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

NextPlat Corp reported substantially improved results for the quarter ended June 30, 2026. Quarterly revenue was $11.9 million, up approximately 21% sequentially from $9.9 million, driven by growth in contracted healthcare services and a 27% sequential increase in e-commerce revenue to $4.1 million. Contracted pharmacy revenue rose to about $2.2 million from $0.9 million in the prior-year quarter, including higher 340B and medication fulfillment revenue, while total pharmacy prescription revenue declined to $5.6 million from $8.2 million due to lower reimbursement rates and payer mix.

Overall gross margin reached a record 40%, up from 35% in the first quarter of 2026 and 22% a year earlier. Healthcare Operations gross margin increased to 46% and e-Commerce margin to 27%. Net loss attributable to common stockholders narrowed to $144,000 (loss of $0.05 per share) from $1.8 million (loss of $0.69 per share), and management states that excluding a one-time $0.5 million increase in professional fees, the company was profitable in the quarter.

NextPlat ended the period with $11.9 million in cash, working capital of $14.2 million, and no material unsecured debt. The company highlighted growing 340B prescription volumes, new contracted entities, government and military e-commerce sales exceeding $1.75 million year-to-date, a planned pharmacy acquisition in Florida, and an expected nationwide medication fulfillment website launch in the third quarter of 2026.

Positive

Net loss cut by 92% year-over-year to $144,000, with management indicating underlying profitability in Q2 2026 excluding a one-time $0.5 million professional-fee increase.
Gross margin expanded to a record 40%, up from 22% in the prior-year quarter, reflecting a shift toward higher-margin healthcare and e-commerce revenues.
Contracted pharmacy revenue grew to $2.2 million from $0.9 million year-over-year, highlighting successful execution of the higher-value 340B and fulfillment strategy.
E-commerce revenue rose 27% sequentially to $4.1 million with improved margins, supported by strong demand from government and military customers.

Negative

Total revenue declined year-over-year to $11.9 million from $13.2 million for Q2, reflecting lower payer reimbursement rates and payer mix in pharmacy prescription revenue.
Six-month revenue decreased to $21.7 million from $27.2 million, indicating that despite Q2 improvement, the first half of 2026 trailed the prior-year period.
Accounts payable and accrued expenses increased to $10.3 million from $8.3 million since year-end 2025, contributing to total liabilities rising to $12.2 million.

Filing Explained

The completed quarter-end filing adds detailed liabilities and reports 2,713,222 common shares outstanding at June 30, 2026.

This Form 8-K records the completed quarter-end financial condition as of June 30, 2026; the added balance-sheet detail shows current liabilities of $10,982 thousand against total assets of $28,672 thousand.

Within those obligations, the company reports notes payable and operating lease liabilities in both current and long-term categories.

The balance sheet reports 2,713,222 common shares issued and outstanding at June 30, 2026, versus 2,676,788 at December 31, 2025; the filing presents the counts but does not establish a resulting ownership percentage for existing holders.

As an Item 2.02 8-K, the report furnishes the results announcement as Exhibit 99.1; the company says the information is not incorporated into other filings unless specifically referenced.

The company directs readers to the Form 10-Q for the quarter ended June 30, 2026, which it says will be filed; that report is the identified path for fuller interim financial-statement and liquidity detail.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Quarterly Revenue: $11,881,000 Sequential Revenue Growth: 21% Gross Margin: 40% +5 more

8 metrics

Quarterly Revenue $11,881,000 Revenue for the three months ended June 30, 2026

Sequential Revenue Growth 21% Increase over first quarter 2026 revenue of $9.9 million

Gross Margin 40% Overall gross margin in Q2 2026, up from 22% in Q2 2025

Net Loss Attributable to Common Stockholders $144,000 Net loss for the three months ended June 30, 2026

Contracted Pharmacy Revenue $2,200,000 Approximate contracted pharmacy revenue in Q2 2026, up from $0.9 million

Cash Balance $11,940,000 Cash as of June 30, 2026

Total Liabilities $12,187,000 Total liabilities as of June 30, 2026

Six-Month Revenue $21,736,000 Revenue for the six months ended June 30, 2026

Key Terms

340B contracted pharmacy services, Medicare Drug Price Negotiation Program, operating right-of-use assets, non-controlling interests, +1 more

5 terms

340B contracted pharmacy services medical

"shift toward higher-margin 340B contracted pharmacy services"

Medicare Drug Price Negotiation Program medical

"lower drug acquisition costs resulting from the Medicare Drug Price Negotiation Program"

A government program that allows the public health insurer Medicare to negotiate lower prices with drug makers for certain prescription medicines, similar to a large buyer using its scale to demand discounts. It matters to investors because negotiated price caps can reduce revenue and profit forecasts for affected drug companies while lowering costs for the healthcare system, which can shift market expectations, valuation models, and competitive dynamics across the pharmaceutical and biotech sectors.

operating right-of-use assets financial

"Operating right-of-use assets, net | | | 572"

Operating right-of-use assets are the recorded value of something a company has the legal right to use under a lease—like equipment, office space, or vehicles—without owning it. Investors care because recognizing these assets (and the matching lease liabilities) changes a company’s balance sheet and key metrics such as leverage and operating profit, similar to how renting furniture would still affect your household budget and long-term obligations.

non-controlling interests financial

"Equity attributable to non-controlling interests | | | 100"

An ownership stake in a subsidiary held by outside shareholders rather than the parent company, representing the portion of that subsidiary’s assets and profits the parent does not control. For investors, it shows what part of consolidated earnings and equity belongs to others — like a roommate who owns part of a house — which affects how much value and profit per share are truly attributable to the parent company’s shareholders.

working capital financial

"The Company ended the quarter with approximately $11.9 million in cash, working capital"

Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.

Earnings Snapshot

Q2 2026 Revenue: $11,881,000 · Guidance included

Quarter and six months ended June 30, 2026

Q2 2026 Revenue $11,881,000 Sequential increase of approximately 21% from $9.9 million; down from $13,240,000 in Q2 2025

Q2 2026 Gross Margin 40% Up from 35% in Q1 2026 and 22% in Q2 2025

Q2 2026 Net Loss Attributable to Common Stockholders $144,000 Decreased approximately 92% from $1,789,000 in Q2 2025

Six-Month 2026 Revenue $21,736,000 Down from $27,166,000 for the six months ended June 30, 2025

Guidance

Management anticipates sustainable positive operating income for the remainder of 2026 and expects positive earnings moving forward, supported by higher-margin contracted healthcare services and an efficient expense structure.

FAQ

How did NextPlat Corp (NXPL) perform financially in Q2 2026?

NextPlat reported $11.9 million in Q2 2026 revenue and a net loss of $144,000. Revenue grew 21% sequentially, gross margin reached 40%, and management notes underlying profitability excluding a one-time $0.5 million professional-fee increase.

How did NextPlat’s Q2 2026 results compare to the prior year for NXPL?

Q2 2026 revenue was $11.9 million versus $13.2 million in Q2 2025, while net loss narrowed to $144,000 from $1.8 million. Gross margin improved significantly to 40%, up from 22% in the prior-year quarter.

What drove margin improvement for NextPlat Corp (NXPL) in Q2 2026?

NextPlat’s overall gross margin reached 40%, helped by Healthcare Operations margin of 46% and e-Commerce margin of 27%. Growth in higher-margin 340B contracted pharmacy services and satellite-based IoT and PTT products supported this expansion.

What is the status of NextPlat’s balance sheet as of June 30, 2026?

As of June 30, 2026, NextPlat had $11.9 million in cash, total assets of $28.7 million, and total liabilities of $12.2 million. Working capital was about $14.2 million, and the company reported no material unsecured debt.

What strategic initiatives did NextPlat Corp (NXPL) highlight for its healthcare business?

NextPlat emphasized higher-margin 340B contracted pharmacy services, signing 11 new entities in the first half of 2026. It also disclosed an intended acquisition of a profitable pharmacy in Northwest Florida and plans to launch a nationwide medication fulfillment website in Q3 2026.

How did NextPlat’s e-commerce segment perform in Q2 2026?

E-commerce revenue increased 27% sequentially to about $4.1 million with gross margin rising to 27%. Growth was driven by satellite-based connectivity, IoT, and Push-to-Talk hardware plus airtime services, with government and military sales surpassing $1.75 million year-to-date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 08/13/2026 - 04:17 PM Accepted by SEC EDGAR 08/13/2026 - 04:16 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 13, 2026

NEXTPLAT CORP

(Exact Name of Registrant as Specified in its Charter)

Nevada		001-40447		65-0783722
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File No.)		(I.R.S. Employer Identification No.)

400 Ansin Blvd, Suite A

Hallandale Beach, FL 33009

(Address of principal executive offices and zip code)

(305) 560-5381

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol (s)		Name of each exchange on which registered
Common Stock, par value $0.0001		NXPL		The Nasdaq Stock Market LLC

Item 2.02. Results of Operations and Financial Condition

On August 13, 2026, NextPlat Corp (the “Registrant”) issued a press release announcing certain financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

Exhibits.

Exhibit No.		Description
99.1		Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEXTPLAT CORP.

	By:	/s/ David Phipps
	Name:	David Phipps
	Title:	Chief Executive Officer and President

Dated: August 13, 2026

Exhibit 99.1

NextPlat Reports 21% Sequential Quarterly Revenue Growth, 87% Reduction in Quarterly Net Loss to $144,000 and Record Gross Margin of Approximately 40%

Growth Momentum Continues Across the Business, Highlighted by Increased Higher-Margin 340B Healthcare Prescription Volumes and Over 27% Sequential Growth in E-Commerce Revenue

HALLANDALE BEACH, FL – August 13, 2026 – NextPlat Corp (NASDAQ: NXPL) (“NextPlat” or the “Company”), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced significantly improved operating results for the second quarter ended June 30, 2026.

“The second quarter of 2026 marked a clear financial inflection point in NextPlat’s turnaround as we generated strong sequential revenue growth, expanded consolidated gross margin to a record 40%, and reduced our net loss to $144,000,” said David Phipps, Chief Executive Officer and President of NextPlat Corp. “NextPlat’s significantly improved financial results reflect a more efficient operating structure and a deliberate shift toward higher-margin 340B contracted pharmacy services. Supported by 11 new contracted entities signed during the first half of 2026 and customer onboarding underway, our focus is now on converting this pipeline into revenue, maintaining margin discipline, and achieving sustainable profitability including selective, strategically aligned acquisitions that can add scale and diversification.”

Second Quarter 2026 Financial Highlights:

●	Consolidated revenue for the quarter ended June 30, 2026, was approximately $11.9 million, a sequential increase of approximately 21% over first quarter 2026 revenue of $9.9 million reflecting the Company’s continued focus on expanding its contracted healthcare business

	○	Second quarter 2026 results reflected continued progress in the Company’s Healthcare operations strategy to expand its higher-value contracted pharmacy services focused on supporting the needs of 340B, long-term care, government and other healthcare providers. Contracted pharmacy revenue increased 136% to approximately $2.2 million, compared with approximately $0.9 million in the prior-year period. The increase was attributable to growth in 340B contract revenue of approximately $0.7 million and the increase in medication fulfillment contract services secured late in 2025, of approximately $0.6 million. The increase in 340B contract revenue was driven by growth in our existing 340B contracts of approximately $0.6 million and an increase in new 340B contract revenue of approximately $0.1 million. On a sequential basis, contracted pharmacy revenue increased approximately 20% from the first quarter of 2026, supported by ongoing business development activity and the addition of multiple new contracted clients. Total pharmacy prescription revenue was approximately $5.6 million, compared with approximately $8.2 million in the prior-year period. As anticipated, the year-over-year change primarily reflected lower payer reimbursement rates and payer mix. The strong growth in contracted pharmacy revenue substantially offset these expected headwinds and demonstrates the increasing contribution from the Company’s expanding contracted services business.

	○	Second quarter 2026 e-Commerce revenue increased approximately 27% sequentially to approximately $4.1 million, compared with approximately $3.2 million in the first quarter of 2026, accompanied by improved gross margin performance. Growth was supported by continued strong global demand for satellite-based connectivity and Internet of Things (IoT) products including new and expanded orders for Iridium and Globalstar devices serving international government and military customers.

●	Overall gross margin for the second quarter ended June 30, 2026, reached a record level of approximately 40%, surpassing the previous record of 35% set in the first quarter ended March 31, 2026, and up approximately 18 percentage points from 22% in the prior-year second quarter.

	○	Gross margin in the Company’s Healthcare Operations segment continued to improve significantly, increasing to approximately 46% in the second quarter of 2026, compared with approximately 39% in the first quarter of 2026 and approximately 20% in the second quarter of 2025. This represents an improvement of nearly seven percentage points sequentially and more than double the gross margin reported in the prior-year period. The increase was primarily attributable to the addition of new contracted medication fulfillment services and lower drug acquisition costs resulting from the Medicare Drug Price Negotiation Program, which commenced in January 2026. With higher-margin 340B contracted services revenue expected to increase, the Company believes the segment’s gross margin will remain well above prior-year levels.

	○	Gross margin for e-Commerce Operations continued to increase sequentially during the second quarter of 2026 to approximately 27% from 25% when compared to the first quarter of 2026 and up from 26% recorded in the second quarter of 2025.

●	Total operating expenses for the quarter ended June 30, 2026 slightly increased to approximately $4.8 million from approximately $4.7 million in the prior year quarter primarily reflecting a $0.5 million increase in professional fees. Excluding a one-time increase in professional fees, overall operating expenses declined approximately 8% due to the Company’s ongoing refocusing and streamlining efforts. Management continues to expect that the addition of higher-margin contracted healthcare services revenue supported by the Company’s more efficient expense structure will contribute to sustainable positive operating income for the remainder of 2026.

●	Net loss attributable to common stockholders for the quarter ended June 30, 2026 decreased approximately 92% to approximately $0.1 million or ($0.05) per diluted share, compared to a net loss attributable to common stockholders of approximately $1.8 million, or ($0.69) per diluted share for the three months ended June 30, 2025. Excluding the one-time impact of approximately $0.5 million in professional fees, the Company achieved profitability during the second quarter and anticipates generating positive earnings moving forward.

●	The Company ended the quarter with approximately $11.9 million in cash, working capital of approximately $14.2 million, and no material unsecured debt as of June 30, 2026.

Organizational Highlights and Recent Business Developments:

●	During the quarter, momentum in the Company’s Healthcare Operations segment continued to build as higher-margin 340B contracted pharmacy services prescription volumes grew over 33% year-over-year, driven primarily by enhanced customer service and support. Successful new 340B business development efforts continued to result in the signing of new services contracts, securing five new entities in the first quarter and six in the second quarter, each representing sequential records. Onboarding of these new customers is currently underway. These additions are expected to contribute to increased revenue throughout the third quarter with a more significant contribution expected early in the fourth quarter.

●	After the close of the second quarter, the Company announced the intended acquisition of a profitable pharmacy operation in the Pensacola area of Northwest Florida. Once completed, this strategic acquisition can enhance the Company’s PharmcoRx pharmacy operation, diversifying and expanding its reach into an underserved market as a platform supporting the launch of new high-value healthcare services for regional providers and patients. The Company is currently exploring additional selective acquisitions that could significantly increase the scale of its brick-and-mortar business in Florida.

●	E-commerce sales during the second quarter continued to produce strong sequential growth including improved margins, driven largely by increased sales of satellite-based IoT and Push-to-Talk (PTT) hardware and higher-margin airtime services in international markets supporting government and military sector customers. Through the end of the second quarter, government and military sector sales surpassed $1.75 million.

●	During the third quarter of 2026, the Company expects to launch its new nationwide medication fulfillment website, providing consumers across all 50 U.S. states with convenient online access to prescription and over-the-counter healthcare products. The new platform is expected to significantly expand PharmcoRx’s reach beyond Florida, establish a scalable national e-commerce sales channel and support future healthcare revenue growth through broader consumer access and new partnership opportunities.

Second Quarter 2026 Conference Call Notification

NextPlat’s Chief Executive Officer and President, David Phipps, its Chief Financial Officer, Amanda Ferrio, and Vice President of Healthcare Operations, Birute Norkute, will host a conference call today, August 13^th at 8:30 a.m. Eastern time to discuss the results for the quarter ended June 30, 2026, as well as other recent developments.

To access the call, please use the following information:

Date:	Thursday, August 13, 2026
Time:	8:30 a.m. Eastern time
Toll-free dial-in number:	1-877-407-9716
International dial-in number:	1-201-493-6779
Conference webcast link:	https://viavid.webcasts.com/starthere.jsp?ei=1770457&tp_key=6a139162d1

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.

The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1770457&tp_key=6a139162d1 and via the investor relations section of the Company’s website at https://ir.nextplat.com/news-events/ir-calendar/detail/20260813-q2-2026-results-conference-call. A replay of the conference call will be available after 12:00 p.m. Eastern time through August 27, 2026.

Toll-free replay number:	1-844-512-2921
International replay number:	1-412-317-6671
Replay entry code:	13761874

The financial information included in this press release should be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, to be filed with the Securities and Exchange Commission.

About NextPlat Corp

NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide. Through acquisitions, joint ventures and collaborations, the Company seeks to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care.

Forward-Looking Statements

Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company’s business and any of its products, services or solutions. The words “believe,” “forecast,” “project,” “intend,” “expect,” “plan,” “should,” “would,” and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company’s ability to launch additional e-commerce capabilities for consumer and healthcare products and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company’s previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

Media and Investor Contact for NextPlat Corp:

Michael Glickman

MWGCO, Inc.

917-397-2272

mike@mwgco.net

NEXTPLAT CORP AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands, except per share data)

(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
Revenues, net	$	11,881		$	13,240		$	21,736		$	27,166
Cost of revenue		7,187			10,357			13,630			21,419
Gross profit		4,694			2,883			8,106			5,747

Operating expenses:
Selling, general and administrative		2,445			1,976			4,421			4,001
Salaries, wages and payroll taxes		2,296			2,561			4,745			5,288
Depreciation and amortization		54			150			119			320
Intangible asset amortization		26			25			51			51
Total operating expenses		4,821			4,712			9,336			9,660

Operating loss		(127	)		(1,829	)		(1,230	)		(3,913	)
Non-operating income		(31	)		(71	)		(2	)		(222	)
Loss before income taxes		(96	)		(1,758	)		(1,228	)		(3,691	)
Income taxes		(48	)		(31	)		(48	)		(40	)
Net loss		(144	)		(1,789	)		(1,276	)		(3,731	)
Net loss attributable to non-controlling interest		—			—			14			—
Net loss attributable to common stockholders	$	(144	)	$	(1,789	)	$	(1,262	)	$	(3,731	)

Comprehensive loss:
Net loss	$	(144	)	$	(1,789	)	$	(1,276	)	$	(3,731	)
Foreign currency (loss) gain		(6	)		(58	)		17			(69	)
Comprehensive loss	$	(150	)	$	(1,847	)	$	(1,259	)	$	(3,800	)

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(144	)	$	(1,789	)	$	(1,262	)	$	(3,731	)
Weighted number of common shares outstanding – basic and diluted		2,708			2,596			2,701			2,596

Basic and diluted loss per share	$	(0.05	)	$	(0.69	)	$	(0.47	)	$	(1.44	)